Cargando…
Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
Ovarian cancer accounts for 3% of the total cancers in women, yet it is the fifth leading cause of cancer deaths among women. The BRCA1/2 germline and somatic mutations confer a deficiency of the homologous recombination (HR) repair pathway. Inhibitors of poly (ADP-ribose) polymerase (PARP), another...
Autores principales: | El Naggar, Olivia, Doyle, Brenna, Mariner, Kelsey, Gilmour, Susan K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230675/ https://www.ncbi.nlm.nih.gov/pubmed/35736348 http://dx.doi.org/10.3390/medsci10020028 |
Ejemplares similares
-
Difluoromethylornithine (DFMO) and Neuroblastoma: A Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023) -
Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci
por: Ayoola, Moses B., et al.
Publicado: (2022) -
Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas
por: Zell, Jason A., et al.
Publicado: (2012) -
Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas
por: Raj, K P, et al.
Publicado: (2013) -
Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways
por: Alhosin, Mahmoud, et al.
Publicado: (2020)